ERBB2 and cancer: This includes inhibitors of HER2, which are far more effective in treating cancers driven by mutational activation of HER2 (Hyman et al., 2018) than cancers driven by amplification and overexpression of HER2 (Burstein et al., 2010; Martin et al., 2013).